Unlocking the Potential of RARRES1: A Pan-Cancer Analysis for Prognosis, Diagnosis, Immunotherapy, and Drug Sensitivity
AYBU AVESIS · 10.06.2024
DOI: 10.26262/jbrt.v31i0.10099 ↗Kurz gefasst
Fachartikel in der Zeitschrift AYBU AVESIS, erschienen am 10.06.2024. Verfasst von Tuğcan Korak und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Retinoic Acid Receptor Responder 1 (RARRES1) participates in cell adhesion, proliferation, and apoptosis during carcinogenesis beyond its putative tumor suppressor functions. The objective of this study was to perform extensive investigation of the expression level, diagnostic, prognostic and immunotherapeutic value of RARRES1 in pan-cancers. In line with these objectives, we systematically analyzed RARRES1 using public datasets (TCGA, GTEx, CPTAC) and various bioinformatic tools (TIMER, UALCAN, GEPIA, TISIDB, SangerBox, LinkedOmics, CancerSEA, CellMiner). RARRES1 expression was frequently reduced in tumor tissues, and elevated levels were mainly linked to a worse prognosis, particularly in PAAD and OV. High diagnostic value for DLBC, LAML, LGG, and PAAD was obtained. Immune correlation analysis of RARRES1 demonstrated associations with various immune cells, especially dendritic cells and M1 macrophages, tumor microenvironment compositions and all checkpoint genes. RARRES1 involvement in essential immune and carcinogenesis signaling pathways was exhibited by GSEA and CancerSEA analyses. RARRES1 showed a significant correlation with the sensitivity of cancers to 11 drugs, four of which are FDA-approved: cyclobenzaprine hydrochloride, midostaurin, tamoxifen, and idebenone. Given the pivotal role of RARRES1 in tumorigenesis, prognosis, diagnosis, tumor immunity, and its correlation with various drug sensitivities, it emerges as a promising biomarker candidate for anticancer immunotherapy.
Schlagwörter
Zitieren
APA
Korak, T., Albayrak, M. G. B., Kasap, Murat, Akpinar, Gurler, & Yanar, S. (2024). Unlocking the Potential of RARRES1: A Pan-Cancer Analysis for Prognosis, Diagnosis, Immunotherapy, and Drug Sensitivity. AYBU AVESIS. https://doi.org/10.26262/jbrt.v31i0.10099
Vancouver
Korak T, Albayrak MGB, Kasap, Murat, Akpinar, Gurler, et al. Unlocking the Potential of RARRES1: A Pan-Cancer Analysis for Prognosis, Diagnosis, Immunotherapy, and Drug Sensitivity. AYBU AVESIS. 2024. doi:10.26262/jbrt.v31i0.10099
BibTeX
@article{Korak2024,
author = {Korak, Tuğcan and Albayrak, Merve Gülşen Bal and Kasap and Murat and Akpinar and Gurler and Yanar, Sevinç},
title = {Unlocking the Potential of RARRES1: A Pan-Cancer Analysis for Prognosis, Diagnosis, Immunotherapy, and Drug Sensitivity},
journal = {AYBU AVESIS},
year = {2024},
doi = {10.26262/jbrt.v31i0.10099}
}
EUVIMED